PTGX – Protagonist Therapeutics Inc
Float Short %
13.81
Margin Of Safety %
-22
Put/Call OI Ratio
0.18
EPS Next Q Diff
0.08
EPS Last/This Y
-6.34
EPS This/Next Y
3.44
Price
82.83
Target Price
101.08
Analyst Recom
1.23
Performance Q
-1.93
Upside
-73.4%
Beta
2.25
Ticker: PTGX
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-01-23 | PTGX | 83.17 | 0.10 | 1.00 | 6782 |
| 2026-01-26 | PTGX | 82.18 | 0.10 | 0.00 | 6790 |
| 2026-01-27 | PTGX | 83.09 | 0.10 | 0.14 | 6814 |
| 2026-01-28 | PTGX | 81.78 | 0.10 | 10.59 | 6854 |
| 2026-01-29 | PTGX | 79.61 | 0.19 | 0.29 | 7418 |
| 2026-01-30 | PTGX | 81.84 | 0.19 | 0.16 | 7566 |
| 2026-02-02 | PTGX | 83.07 | 0.19 | 0.06 | 7540 |
| 2026-02-03 | PTGX | 85.58 | 0.20 | 0.00 | 7479 |
| 2026-02-04 | PTGX | 83.39 | 0.20 | 2.03 | 7483 |
| 2026-02-05 | PTGX | 80.68 | 0.19 | 0.80 | 7452 |
| 2026-02-06 | PTGX | 84.4 | 0.19 | 0.00 | 7448 |
| 2026-02-09 | PTGX | 83.32 | 0.19 | 3.57 | 7447 |
| 2026-02-10 | PTGX | 83.87 | 0.19 | 0.00 | 7461 |
| 2026-02-11 | PTGX | 83.43 | 0.19 | 0.05 | 7461 |
| 2026-02-12 | PTGX | 81.88 | 0.19 | 0.83 | 7452 |
| 2026-02-13 | PTGX | 81.5 | 0.19 | 0.00 | 7453 |
| 2026-02-17 | PTGX | 82.46 | 0.19 | 0.01 | 7459 |
| 2026-02-18 | PTGX | 82.82 | 0.19 | 0.00 | 7463 |
| 2026-02-20 | PTGX | 82.84 | 0.18 | 0.21 | 7833 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-01-23 | PTGX | 83.12 | -128.3 | - | -1.87 |
| 2026-01-26 | PTGX | 82.18 | -128.3 | - | -1.87 |
| 2026-01-27 | PTGX | 83.11 | -128.3 | - | -1.87 |
| 2026-01-28 | PTGX | 81.82 | -128.3 | - | -1.87 |
| 2026-01-29 | PTGX | 79.71 | -128.3 | - | -1.87 |
| 2026-01-30 | PTGX | 81.81 | -128.3 | - | -1.87 |
| 2026-02-02 | PTGX | 83.11 | -128.3 | - | -1.87 |
| 2026-02-03 | PTGX | 85.52 | -127.3 | - | -1.87 |
| 2026-02-04 | PTGX | 83.32 | -127.3 | - | -1.87 |
| 2026-02-05 | PTGX | 80.71 | -127.3 | - | -1.87 |
| 2026-02-06 | PTGX | 84.47 | -127.3 | - | -1.87 |
| 2026-02-09 | PTGX | 83.20 | -127.3 | - | -1.87 |
| 2026-02-10 | PTGX | 83.87 | -127.3 | - | -1.87 |
| 2026-02-11 | PTGX | 83.44 | -127.3 | - | -1.87 |
| 2026-02-12 | PTGX | 81.89 | -127.3 | - | -1.87 |
| 2026-02-13 | PTGX | 81.48 | -127.3 | - | -1.87 |
| 2026-02-17 | PTGX | 82.38 | -127.3 | - | -1.87 |
| 2026-02-18 | PTGX | 83.00 | -127.3 | - | -1.87 |
| 2026-02-19 | PTGX | 82.96 | -127.3 | - | -1.87 |
| 2026-02-20 | PTGX | 82.83 | -127.3 | - | -1.87 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-01-23 | PTGX | -3.68 | -0.44 | 12.38 |
| 2026-01-26 | PTGX | -2.32 | -0.49 | 12.37 |
| 2026-01-27 | PTGX | -2.35 | -0.49 | 12.37 |
| 2026-01-28 | PTGX | -5.41 | -0.49 | 14.07 |
| 2026-01-29 | PTGX | -5.14 | -0.49 | 14.07 |
| 2026-01-30 | PTGX | -5.14 | -0.49 | 14.07 |
| 2026-02-02 | PTGX | -5.14 | -0.54 | 14.07 |
| 2026-02-03 | PTGX | -5.20 | -0.54 | 14.07 |
| 2026-02-04 | PTGX | -5.20 | -0.54 | 14.07 |
| 2026-02-05 | PTGX | -5.20 | -0.54 | 14.07 |
| 2026-02-06 | PTGX | -5.70 | -0.54 | 14.07 |
| 2026-02-10 | PTGX | -5.70 | 4.22 | 14.07 |
| 2026-02-11 | PTGX | -5.70 | 4.22 | 13.79 |
| 2026-02-12 | PTGX | -5.70 | 4.22 | 13.79 |
| 2026-02-13 | PTGX | -5.70 | 4.22 | 13.79 |
| 2026-02-17 | PTGX | -5.70 | 10.32 | 13.79 |
| 2026-02-18 | PTGX | -6.16 | 10.32 | 13.79 |
| 2026-02-19 | PTGX | -6.16 | 10.32 | 13.79 |
| 2026-02-20 | PTGX | -6.16 | 10.32 | 13.81 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.62
Avg. EPS Est. Current Quarter
-0.56
Avg. EPS Est. Next Quarter
-0.54
Insider Transactions
-6.16
Institutional Transactions
10.32
Beta
2.25
Average Sales Estimate Current Quarter
34
Average Sales Estimate Next Quarter
21
Fair Value
64.73
Quality Score
54
Growth Score
58
Sentiment Score
97
Actual DrawDown %
14.2
Max Drawdown 5-Year %
-85.8
Target Price
101.08
P/E
130.66
Forward P/E
56.84
PEG
P/S
24.73
P/B
8.01
P/Free Cash Flow
81.21
EPS
0.63
Average EPS Est. Cur. Y
-1.87
EPS Next Y. (Est.)
1.57
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
21.94
Relative Volume
0.7
Return on Equity vs Sector %
-21.9
Return on Equity vs Industry %
-4.4
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
Protagonist Therapeutics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 128
Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide therapeutics for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide, an injectable mimetic of hepcidin that is in phase 3 clinical trials for the treatment of polycythemia vera; Icotrokinra, an orally delivered investigational drug which is in phase 3 clinical trials indicated to block biological pathways targeted by marketed injectable antibody drugs; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company also develops IL-17 oral peptide antagonist PN-88,1 an oral metabolic/obesity peptide program, and an oral hepcidin mimetic/ferroportin blocker that is in pre-clinical stage. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
stock quote shares PTGX – Protagonist Therapeutics Inc Stock Price stock today
news today PTGX – Protagonist Therapeutics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch PTGX – Protagonist Therapeutics Inc yahoo finance google finance
stock history PTGX – Protagonist Therapeutics Inc invest stock market
stock prices PTGX premarket after hours
ticker PTGX fair value insiders trading